Verastem (VSTM) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed Verastem (VSTM) over the past year, gaining 5.3% versus a loss of 9.3%. Over five years, ZVRA leads with a +16.6% price change compared with -75.5% for VSTM. Verastem is the larger company by market cap ($758.9 million vs $676.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VSTM | ZVRA |
|---|---|---|
| Share price | $8.38 | $11.39 |
| Market cap | $758.92M | $676.38M |
| 1-day change | +3.33% | +3.55% |
| YTD return | +5.05% | +27.12% |
| 1-year return | -9.28% | +5.27% |
| 5-year return | -75.51% | +16.58% |
| P/E ratio (TTM) | — | 12.38 |
| Forward P/E | — | 10.58 |
| EPS (TTM) | $-2.45 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.82 | $15.04 |
| 52-week low | $3.43 | $8.01 |
| Distance from 52-week high | -22.55% | -24.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +79.00% | +119.49% |
| Average volume | 2.25M | 1.11M |
| Shares outstanding | 90.56M | 59.38M |
| Employees | 102 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed VSTM by 14.6 percentage points over the past year.
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
VSTM vs ZVRA FAQ
Which is bigger, Verastem or Zevra Therapeutics?
Verastem (VSTM) is larger, with a market capitalization of $758.92M compared with $676.38M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, VSTM or ZVRA?
ZVRA returned +5.27% over the past 12 months, compared with -9.28% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Verastem and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.